Immunotherapy in Daily Clinical Practice
Symposium
Symposium

Immunotherapy in Daily Clinical Practice

Clinical Application and Emerging Opportunities

Not a member of My prIME? Join now for instant access.

Meeting Overview

This live meeting will enhance your knowledge of the clinical application of checkpoint inhibitors to the treatment pathways for lung, bladder, and head & neck cancer (H&N). Emerging data about checkpoint inhibitors in prostate, breast, ovarian, and colorectal cancer will also be discussed. This symposium will have a highly interactive and case-based expert panel discussion, facilitating a better understanding of how immunotherapy should be applied in clinical practice.

ESMO 2018 Industry Satellite Symposium

Date and Location

Friday, 19 October 2018
18.00 – 20.00

ICM – Room 13
Messe Munich
Munich, Germany

Date/Time

Date/Time

Friday, 19 October 2018
18.00 – 20.00

Location

Location

Munich, Germany

CME

CME

2.0AMA PRA Category 1 Credits™

Friday, 19 October 2018

18.00 Welcome and introduction
Giuseppe Curigliano, MD, PhD
18.05 Patient selection for immunotherapy: Making sense of current and emerging biomarkers
Mario Colombo, PhD

Coping With the Whirlwind of Change in Lung Cancer Treatment: A Multidisciplinary Team Discussion

18.17 Clinical scenario 1: First-line therapy for metastatic lung cancer
David Planchard, MD, PhD
18.29 Clinical scenario 2: Locally advanced lung cancer
David Planchard, MD, PhD
18.41 Q & A

The Emerging Role for Immunotherapy in H&N Cancer: A Multidisciplinary Team Discussion

18.45 Clinical scenario 1: Platinum-resistant advanced H&N cancer
Jean-Pascal Machiels, MD, PhD
18.57 Q & A

The Expanding Role of Immunotherapy for Urologic Malignancies: A Multidisciplinary Team Discussion

19.00 Clinical scenario 1: First-line therapy for metastatic bladder cancer
David I. Quinn, MBBS, PhD, FRACP, FACP
19.12 Clinical scenario 2: Second-line therapy for metastatic bladder cancer
David I. Quinn, MBBS, PhD, FRACP, FACP
19.24 Clinical scenario 3: A patient with BRCA-positive, endocrine-resistant metastatic prostate cancer
David I. Quinn, MBBS, PhD, FRACP, FACP
19.36 Q & A
19.39 Extending immunotherapy beyond established indications
Giuseppe Curigliano, MD, PhD
19.51 Q & A
19.53 Reprise of questions from introduction
Giuseppe Curigliano, MD, PhD
19.58 Conclusions and prIME Points™
Giuseppe Curigliano, MD, PhD
20.00 Adjourn

Faculty

    Chair

  • Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
    University of Milan
    Milan, Italy
  • Faculty

  • Mario Colombo, PhDFondazione IRCCS - Istituto Nazionale dei Tumori
    Milan, Italy
  • Jean-Pascal Machiels, MD, PhDCliniques universitaires Saint-Luc
    Université catholique de Louvain
    Brussels, Belgium
  • David Planchard, MD, PhDGustave Roussy
    Villejuif, France
  • David I. Quinn, MBBS, PhD, FRACP, FACPUniversity of Southern California
    Norris Cancer Hospital
    Los Angeles, California, United States

This educational activity is intended for medical oncologists and other healthcare professionals interested in immunotherapy approaches for solid tumors.

After successful completion of this educational activity, participants should be able to:

  • Describe the clinical application of checkpoint inhibitors to the treatment pathways for lung, bladder, and H&N cancer
  • Discuss the current and emerging data with checkpoint inhibition in prostate, breast, ovarian, and colorectal cancer
  • Apply the use of biomarkers to guide treatment selection
  • Incorporate multidisciplinary strategies to monitor and manage immune-related adverse events

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME Practice

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.